Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Klaria Pharma Holding AB: Klaria Year-End Report 2023

Klaria Pharma Holding
Download the release

Summary of the interim report

Fourth quarter of 2023

Remaining business operations

- Net sales 0.0 MSEK (2.2 MSEK)

- Other income 0.2 MSEK (0.2 MSEK)

- R&D costs for the quarter amounted to 1.5 MSEK (8.6 MSEK)

- Profit after tax amounted to -7.9 MSEK (-12.9 MSEK)

- Earnings per share for the quarter amounted to -0.07 SEK (-0.22 SEK)

- Cash flow from operating activities amounted to -13.3 MSEK (-10.7 MSEK)

Business operations for sale

- Profit after tax amounted to -1.6 MSEK

The period January-December 2023

Remaining business operations

- Net sales 0.0 MSEK (5.9 MSEK)

- Other income 0.2 MSEK (0.7 MSEK)

- R&D costs for the period amounted to 4.5 MSEK (51.4 MSEK)

- Profit after tax amounted to -18.4 MSEK (-63.8 MSEK)

- Earnings per share for the period amounted to -0.18 SEK (-1.10 SEK)

- Cash flow from operating activities amounted to -15.4 MSEK (-49.8 MSEK)

Business operations for sale

- Profit after tax amounted to -17.4 MSEK

- Earnings per share for the quarter amounted to -0.17 SEK

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.